Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Hemophilia Therapeutics market. The report identifies the key trends shaping and driving the global Hemophilia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hemophilia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Hemophilia Therapeutics market. Its Scope includes -
The report will enhance your decision making capability. It will allow you to -
Summary
GlobalData, the industry analysis specialist, has released its new report, “Hemophilia Therapeutics - Pipeline Assessment and Market Forecasts to 2018”. The report is an essential source of information and analysis on the global Hemophilia Therapeutics market. The report identifies the key trends shaping and driving the global Hemophilia Therapeutics market. The report also provides insights on the prevalent competitive landscape and the emerging players expected to significantly alter the market positioning of the current market leaders. Most importantly, the report provides valuable insights on the pipeline products within the global Hemophilia Therapeutics sector. This report is built using data and information sourced from proprietary databases, primary and secondary research and in-house analysis by GlobalData’s team of industry experts.
Scope
The report provides information on the key drivers and challenges of the Hemophilia Therapeutics market. Its Scope includes -
- Annualized seven key markets (US, France, Germany, Italy, Spain, UK and Japan) Hemophilia Therapeutics market revenues data from 2005 to 2009, forecast for eight years to 2017.
- Pipeline analysis data providing a split across the different phases, mechanisms of action being developed and emerging trends by seven key markets. Pipeline candidates fall under major therapeutic classes.
- Analysis of the current and future competition in the seven key countries Hemophilia Therapeutics market.
- Insightful review of the key industry drivers, restraints and challenges. Each trend is independently researched to provide a qualitative analysis of its implications.
- Key topics covered include strategic competitor assessment, market characterization, unmet needs and the implications for the Hemophilia Therapeutics market.
- Analysis of key recent licensing and partnership agreements in Hemophilia Therapeutics market
The report will enhance your decision making capability. It will allow you to -
- Develop and design your in-licensing and out-licensing strategies through a review of pipeline products and technologies and by identifying the companies with the most robust pipeline.
- Develop business strategies by understanding the trends shaping and driving the global Hemophilia Therapeutics market.
- Drive revenues by understanding the key trends, innovative products and technologies, market segments and companies likely to impact the global Hemophilia Therapeutics market in future.
- Formulate effective sales and marketing strategies by understanding the competitive landscape and by analyzing the performance of various competitors.
- Identify emerging players with potentially strong product portfolios and create effective counter-strategies to gain a competitive advantage.
- Organize your sales and marketing efforts by identifying the market categories and segments that present maximum opportunities for consolidations, investments and strategic partnerships.
- What’s the next big thing in the global Hemophilia Therapeutics market landscape? - Identify, understand and capitalize.
Contents
1 TABLE OF CONTENTS1.1 List of Tables
1.2 List of Figures
2 HEMOPHILIA THERAPEUTICS - INTRODUCTION
2.1 Disease Overview
2.2 Classification of Hemophilia and Other Bleeding Disorders
2.2.1 Classification of Hemophilia on the Basis of Coagulation Factor Deficiency
2.2.2 Classification of Hemophilia on the Basis of Bleeding Manifestations
2.2.3 Other Bleeding Disorders
2.3 Epidemiology
2.4 Etiology
2.5 Sign and Symptoms
2.6 Diagnosis
2.7 Treatment and Management of Hemophilia
2.7.1 Factor Concentrates
2.7.2 Whole Blood
2.7.3 Fresh Plasma
2.7.4 Desmopressin (DDAVP)
2.7.5 Antifibrinolytic agents
2.7.6 Inhibitors
2.7.7 Gene Therapy
2.7.8 Advantages and Disadvantages of Treatment Methods of Hemophilia
2.8 Management of Hemophilia
2.9 Acquired Hemophilia
2.9.1 Treatment of Acquired Hemophilia
2.10 GlobalData Pipeline Report Guidance
3 HEMOPHILIA THERAPEUTICS - MARKET CHARACTERIZATION
3.1 Hemophilia Therapeutics Market Size (2005-2010) - Global
3.2 Hemophilia Therapeutics Market Forecast (2010-2018) – Global
3.3 Hemophilia Therapeutics Market Size (2005-2010) - The US
3.4 Hemophilia Therapeutics Market Forecast (2010-2018) - The US
3.5 Hemophilia Therapeutics Market Size (2005-2010) - France
3.6 Hemophilia Therapeutics Market Forecast (2010-2018) - France
3.7 Hemophilia Therapeutics Market Size (2005-2010) - Germany
3.8 Hemophilia Therapeutics Market Forecast (2010-2018) - Germany
3.9 Hemophilia Therapeutics Market Size (2005-2010) - Italy
3.10 Hemophilia Therapeutics Market Forecast (2010-2018) - Italy
3.11 Hemophilia Therapeutics Market Size (2005-2010) - Spain
3.12 Hemophilia Therapeutics Market Forecast (2010-2018) - Spain
3.13 Hemophilia Therapeutics Market Size (2005-2010) - The UK
3.14 Hemophilia Therapeutics Market Forecast (2010-2018) - The UK
3.15 Hemophilia Therapeutics Market Size (2005-2010) - Japan
3.16 Hemophilia Therapeutics Market Forecast (2010-2018) - Japan
3.17 Drivers and Barriers for the Hemophilia Therapeutics Market
3.17.1 Drivers for the Hemophilia Therapeutics Market
3.17.2 Barriers for the Hemophilia Therapeutics Market
3.18 Opportunity and Unmet Need
3.18.1 Opportunity and Unmet Need for Hemophilia A
3.18.2 Opportunity and Unmet Need for Hemophilia B
3.18.3 Opportunity and Unmet Need for Hemophilia A and B Patients with Inhibitors
3.19 Key Takeaway
4 HEMOPHILIA THERAPEUTICS MARKET - COMPETITIVE ASSESSMENT
4.1 Hemophilia Therapeutics Market – Overview
4.2 Strategic Competitor Assessment
4.2.1 Competitor Assessment Within Different Therapeutic Categories Employed in Hemophilia Treatment
4.3 Product Profile for the Major Marketed Products in the Hemophilia Therapeutics Market
4.3.1 NovoSeven (Coagulation Factor VIIa)
4.3.2 Advate (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free Method)
4.3.3 Kogenate FS (Antihemophilic Factor (Recombinant) Formulated with Sucrose)
4.3.4 XYNTHA (Antihemophilic Factor (Recombinant), Plasma/Albumin-Free)
4.3.5 BeneFIX (Coagulation Factor IX (Recombinant))
4.3.6 Monoclate-P (Antihemophilic factor (human) Factor VIII: C pasteurized monoclonal antibody purified)
4.3.7 Mononine (Coagulation factor IX (human))
4.3.8 FEIBA-VH (Anti-Inhibitor Coagulant Complex)
4.4 Key Takeaway
5 HEMOPHILIA THERAPEUTICS - PIPELINE ASSESSMENT
5.1 Overview
5.2 Strategic Pipeline Assessment
5.3 Hemophilia Pipeline – Pipeline by Phases of Development
5.3.1 Hemophilia Therapeutics – Pre-registration
5.3.2 Hemophilia Therapeutics – Phase III Pipeline
5.3.3 Hemophilia Therapeutics – Phase II Pipeline
5.3.4 Hemophilia Therapeutics – Phase I/II Pipeline
5.3.5 Hemophilia Therapeutics – Phase I Pipeline
5.3.6 Hemophilia Therapeutics – Preclinical Pipeline
5.3.7 Hemophilia Therapeutics – Discovery Pipeline
5.4 Hemophilia Therapeutics – Pipeline by Mechanism of Action
5.5 Hemophilia Therapeutics – Pipeline by Therapeutic Class
5.5.1 Technology Trends Analytic Framework
5.6 Hemophilia Therapeutics – Promising Drugs under Clinical Development
5.7 Molecule Profile for Promising Drugs Under Clinical Development
5.7.1 NecLip-pdFVIII (LongAte)
5.7.2 Human-cl rhFVIII
5.7.3 NN7008 (recombinant factor VIII or rFVIII)
5.7.4 NN7999 (N9-GP, rFIX glycopegylated)
5.7.5 Kogenate PF (recombinant factor VIII, BAY81-8973)
5.7.6 Long Lasting rFactor VIII Fc Fusion Protein (rFVIIIFc)
5.7.7 Long Lasting rFactor IX Fc Fusion Protein (rFIXFc)
5.7.8 IB1001 (Recombinant Factor IX)
5.7.9 OBI-1 (rpFVIII)
5.7.10 BAX 326
5.7.11 FEIBA NF
5.7.12 Biostate
5.8 Key Takeaway
6 HEMOPHILIA THERAPEUTICS - CLINICAL TRIALS MAPPING
6.1 Clinical Trials by Country (US, EU5 and Japan)
6.2 Clinical Trials by Phase
6.3 Clinical Trials by Status
6.4 Overall Sponsors
6.5 Prominent Sponsors
6.6 Top Companies Participating in Hemophilia Therapeutics Clinical Trials
7 HEMOPHILIA THERAPEUTICS - STRATEGIC ASSESSMENT
7.1 Hemophilia Therapeutics: Implications for Future Market Competition
8 HEMOPHILIA THERAPEUTICS - FUTURE PLAYERS
8.1 Introduction
8.2 Company Profiles
8.2.1 Baxter International Inc.
8.2.2 Recoly NV
8.2.3 Bayer AG
8.2.4 Novo Nordisk A/S
8.2.5 CSL Limited
8.2.6 Octapharma AG
8.2.7 Biogen Idec
8.2.8 Inspiration Biopharmaceuticals, Inc
8.2.9 Ipsen S.A.
8.2.10 Other Companies in the Hemophilia Therapeutics Market
9 HEMOPHILIA THERAPEUTICS - LICENSING AND PARTNERSHIP DEALS10 HEMOPHILIA THERAPEUTICS - APPENDIX
10.1 Market Definitions
10.2 Abbreviations
10.3 Methodology
10.3.1 Coverage
10.3.2 Secondary Research
10.3.3 Forecasting
10.3.4 Primary Research
10.3.5 Expert Panel Validation
10.4 Contact Us
10.5 Disclaimer
10.6 Bibliography
LIST OF TABLES
Table 1: Bleeding Manifestations in Hemophilia
Table 2: Hemophilia, Patients Diagnosed in 2009
Table 3: Hematology Laboratory Tests
Table 4: Consumption Breakdown of Factor Concentrates
Table 5: Characteristics of Factor VIII Replacement Products
Table 6: Characteristics of Factor IX Replacement Products
Table 7: Characteristics of Bypassing Agents
Table 8: Hemophilia Therapeutics Market, Global, Revenue ($m), 2005–2010
Table 9: Hemophilia Therapeutics Market, Global, Forecast ($m), 2010–2018
Table 10: Hemophilia Therapeutics Market, The US, Revenue ($m), 2005–2010
Table 11: Hemophilia Therapeutics Market, The US, Forecast ($m), 2010–2018
Table 12: Hemophilia Therapeutics Market, France, Revenue ($m), 2005–2010
Table 13: Hemophilia Therapeutics Market, France, Forecast ($m), 2010–2018
Table 14: Hemophilia Therapeutics Market, Germany, Revenue ($m), 2005–2010
Table 15: Hemophilia Therapeutics Market, Germany, Forecast ($m), 2010–2018
Table 16: Hemophilia Therapeutics Market, Italy, Revenue ($m), 2005–2010
Table 17: Hemophilia Therapeutics Market, Italy, Forecast ($m), 2010–2018
Table 18: Hemophilia Therapeutics Market, Spain, Revenue ($m), 2005–2010
Table 19: Hemophilia Therapeutics Market, Spain, Forecast ($m), 2010–2018
Table 20: Hemophilia Therapeutics Market, The UK, Revenue ($m), 2005–2010
Table 21: Hemophilia Therapeutics Market, The UK, Forecast ($m), 2010–2018
Table 22: Hemophilia Therapeutics Market, Japan, Revenue ($m), 2005–2010
Table 23: Hemophilia Therapeutics Market, Japan, Forecast ($m), 2010–2018
Table 24: Major Brands - Usage in Hemophilia Therapeutics Market
Table 25: Approval and Launch Dates of Major Brands in Hemophilia Therapeutics Market
Table 26: Hemophilia Therapeutics – Pre-registration, 2011
Table 27: Hemophilia Therapeutics – Phase III Pipeline, 2011
Table 28: Hemophilia Therapeutics – Phase II Pipeline, 2011
Table 29: Hemophilia Therapeutics – Phase I/II Pipeline, 2011
Table 30: Hemophilia Therapeutics – Phase I Pipeline, 2011
Table 31: Hemophilia Therapeutics – Preclinical Pipeline, 2011
Table 32: Hemophilia Therapeutics – Discovery Pipeline, 2011
Table 33: Mechanism of Action for the ‘Other’ molecules in the Figure Above
Table 34: Hemophilia Therapeutics – Promising Drugs Under Clinical Development, 2011
Table 35: Hemophilia Therapeutics – Clinical Trials by Country, 2011
Table 36: Hemophilia Therapeutics – Clinical Trials by Phase, 2011
Table 37: Hemophilia Therapeutics – Clinical Trials by Status, 2011
Table 38: Hemophilia Therapeutics – Overall Sponsors, 2011
Table 39: Hemophilia Therapeutics –Prominent Sponsors, 2011
Table 40: Hemophilia Therapeutics: Top Companies Participating in Therapeutics Clinical Trials, 2011
Table 41: Baxter - Hemophilia Pipeline 2011
Table 42: Recoly NV - Hemophilia Pipeline 2011
Table 43: Bayer - Hemophilia pipeline 2011
Table 44: Novo Nordisk - Hemophilia Pipeline 2011
Table 45: CSL Limited - Hemophilia Pipeline 2011
Table 46: Octapharma AG - Hemophilia Pipeline 2011
Table 47: Biogen Idec. - Hemophilia Pipeline 2011
Table 48: Inspiration Biopharmaceuticals, Inc. - Hemophilia Pipeline 2011
Table 49: Ipsen SA - Hemophilia Pipeline 2011
Table 50: Hemophilia Therapeutics Market – Other Future Players, 2011
Table 51: Hemophilia Therapeutics, Licensing and Partnership Deals, 2011
LIST OF FIGURES
Figure 1: The Coagulation Cascade
Figure 2: Patients Diagnosed in 2009
Figure 3: Proportional Usage of Plasma Versus Recombinant Factor VIII for Hemophilia A Patients Reported in WFH Survey 2009
Figure 4: Proportional Usage of Plasma Versus Recombinant Factor IX for Hemophilia B Patients Reported in WFH Survey 2009
Figure 5: Advantages and Disadvantages of Treatment Methods of Hemophilia
Figure 6: Key Aspects of Management of Hemophilia
Figure 7: Hemophilia A Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 8: Hemophilia B Therapeutics Market, Global, Revenue ($m), 2005-2010
Figure 9: Hemophilia Therapeutics (A&B), Global, Market Share (%), 2010
Figure 10: Hemophilia A Therapeutics Market, Global, Forecasts ($m), 2010-2018
Figure 11: Hemophilia B Therapeutics Market, Global, Forecasts ($m), 2010-2018
Figure 12: Hemophilia Therapeutics (A&B), Global, Market Share (%), 2018
Figure 13: Hemophilia A Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 14: Hemophilia B Therapeutics Market, The US, Revenue ($m), 2005-2010
Figure 15: Hemophilia Therapeutics (A&B), The US, Market Share (%), 2010
Figure 16: Hemophilia A Therapeutics Market, The US, Forecasts ($m), 2010-2018
Figure 17: Hemophilia B Therapeutics Market, The US, Forecasts ($m), 2010-2018
Figure 18: Hemophilia Therapeutics (A&B), The US, Market Share (%), 2018
Figure 19: Hemophilia A Therapeutics Market, France, Forecast ($m), 2005-2010
Figure 20: Hemophilia B Therapeutics Market, France, Revenue ($m), 2005-2010
Figure 21: Hemophilia Therapeutics (A&B), France, Market Share (%), 2010
Figure 22: Hemophilia A Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 23: Hemophilia B Therapeutics Market, France, Forecast ($m), 2010-2018
Figure 24: Hemophilia Therapeutics (A&B), France, Market Share (%), 2018
Figure 25: Hemophilia A Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 26: Hemophilia B Therapeutics Market, Germany, Revenue ($m), 2005-2010
Figure 27: Hemophilia Therapeutics (A&B), Germany, Market Share (%), 2010
Figure 28: Hemophilia A Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 29: Hemophilia B Therapeutics Market, Germany, Forecast ($m), 2010-2018
Figure 30: Hemophilia Therapeutics (A&B), Germany, Market Share (%), 2018
Figure 31: Hemophilia A Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 32: Hemophilia B Therapeutics Market, Italy, Revenue ($m), 2005-2010
Figure 33: Hemophilia Therapeutics (A&B), Italy, Market Share (%), 2010
Figure 34: Hemophilia A Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 35: Hemophilia A Therapeutics Market, Italy, Forecast ($m), 2010-2018
Figure 36: Hemophilia Therapeutics (A&B), Italy, Market Share (%), 2018
Figure 37: Hemophilia A Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 38: Hemophilia B Therapeutics Market, Spain, Revenue ($m), 2005-2010
Figure 39: Hemophilia Therapeutics (A&B), Spain, Market Share (%), 2010
Figure 40: Hemophilia A Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 41: Hemophilia B Therapeutics Market, Spain, Forecast ($m), 2010-2018
Figure 42: Hemophilia Therapeutics (A&B), Spain, Market Share (%), 2018
Figure 43: Hemophilia A Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 44: Hemophilia B Therapeutics Market, The UK, Revenue ($m), 2005-2010
Figure 45: Hemophilia Therapeutics (A&B), The UK, Market Share (%), 2010
Figure 46: Hemophilia A Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 47: Hemophilia B Therapeutics Market, The UK, Forecast ($m), 2010-2018
Figure 48: Hemophilia Therapeutics (A&B), The UK, Market Share (%), 2018
Figure 49: Hemophilia A Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 50: Hemophilia B Therapeutics Market, Japan, Revenue ($m), 2005-2010
Figure 51: Hemophilia Therapeutics (A&B), Japan, Market Share (%), 2010
Figure 52: Hemophilia A Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 53: Hemophilia B Therapeutics Market, Japan, Forecast ($m), 2010-2018
Figure 54: Hemophilia Therapeutics (A&B), Japan, Market Share (%), 2018
Figure 55: Hemophilia Market, Drivers and Barriers, 2011
Figure 56: Opportunity and Unmet Need for Hemophilia A Therapeutics Market, 2011
Figure 57: Opportunity and Unmet Need for Hemophilia B Therapeutics Market, 2011
Figure 58: Opportunity and Unmet Need for Hemophilia A&B Inhibitors Therapeutics Market, 2011
Figure 59: Hemophilia A Therapeutics – Strategic Competitor Assessment, 2011
Figure 60: Hemophilia B Therapeutics – Strategic Competitor Assessment, 2011
Figure 61: Hemophilia A and B with Inhibitors Therapeutics, 2011
Figure 62: Hemophilia Therapeutics – Pipeline by Phase of Development, 2011
Figure 63: Hemophilia Therapeutics – Clinical Pipeline by Mechanism Of Action, 2011
Figure 64: Hemophilia Therapeutics – Clinical Pipeline by Therapeutic Class, 2011
Figure 65: Hemophilia Therapeutics – Technology Trends Analytics Framework, 2011
Figure 66: Hemophilia Therapeutics – Technology Trends Analytics Framework – Description, 2011
Figure 67: Hemophilia Therapeutics – Clinical Trials by Country, 2011
Figure 68: Hemophilia Therapeutics – Clinical Trials by Phase, 2011
Figure 69: Hemophilia Therapeutics – Clinical Trials by Status, 2011
Figure 70: Hemophilia Therapeutics – Overall Sponsors, 2011
Figure 71: Hemophilia Therapeutics – Prominent Sponsors, 2011
Figure 72: Hemophilia Therapeutics – Top Companies Participating in Clinical Trials, 2011
Figure 73: Implications for Future Market Competition in Hemophilia Therapeutics Market, 2011
Figure 74: Hemophilia – Pipeline by Company, 2011
Figure 75: GlobalData Market Forecasting Model
COMPANIES MENTIONED
Baxter International Inc.
Recoly NV
Bayer AG
Novo Nordisk A/S
CSL Limited
Octapharma AG
Biogen Idec
Inspiration Biopharmaceuticals, Inc
Ipsen S.A. Skip to top